Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-acting injectable ART in adolescents with HIV
PACTR202605905512833Phase 3Unknown
- Sponsor
- Desmond Tutu Health Foundation
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cabotegravir and rilpivirine in human immunodeficiency virus infection (HIV), sponsored by Desmond Tutu Health Foundation. Primary endpoints: Acceptability of injectable ART delivery, Feasibility of community delivery and 1 more. Status: unknown.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202605905512833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605905512833.